2021 doi All icons above are courtesy of Jonathan K Ramsey MD CFTR Modulator Use is Associated with Reduced Acute Pancreatitis Hospitalizations Population Outcome Conclusion Cystic fibrosis patients with CFTR modulator exposure in MarketScan n1795 ID: 1042681
Download Presentation The PPT/PDF document "Ramsey et al. Am J Gastroenterol" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Ramsey et al. Am J Gastroenterol. 2021. [doi]All icons above are courtesy of Jonathan K. Ramsey, MD. CFTR Modulator Use is Associated with Reduced Acute Pancreatitis HospitalizationsPopulationOutcomeConclusionCystic fibrosis patients with CFTR modulator exposure in MarketScan (n=1,795)Acute pancreatitis hospitalizations, analyzed by time-varying covariate based on CFTR modulator useCFTR modulators reduce AP by 64% in PS-CF and 49% in PI-CF among subjects eligible for CFTR modulator treatment.Estimated rate of AP per 1,000 patient-years:*Adjusted for ageWithout modulatorsWith CFTR modulatorsPS-CF12.934.65PI-CF0.670.34